> Details

Blanco Dorado, Sara; Maroñas Amigo, Olalla; Latorre‐Pellicer, Ana; Rodríguez Jato, María Teresa; López‐Vizcaíno, Ana; Gómez Márquez, Aurea; Bardán García, Belén; Belles Medall, Dolores; Barbeito Castiñeiras, Gema; Pérez del Molino Bernal, María Luisa; Campos‐Toimil, Manuel; Otero Espinar, Francisco; Blanco Hortas, Andrés; Zarra Ferro, Irene; Carracedo, Ángel; Lamas, María Jesús; Fernández‐Ferreiro, Anxo

A multicentre prospective study evaluating the impact of proton‐pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: A multicentre prospective study evaluating the impact of proton‐pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations
  • Contributor: Blanco Dorado, Sara; Maroñas Amigo, Olalla; Latorre‐Pellicer, Ana; Rodríguez Jato, María Teresa; López‐Vizcaíno, Ana; Gómez Márquez, Aurea; Bardán García, Belén; Belles Medall, Dolores; Barbeito Castiñeiras, Gema; Pérez del Molino Bernal, María Luisa; Campos‐Toimil, Manuel; Otero Espinar, Francisco; Blanco Hortas, Andrés; Zarra Ferro, Irene; Carracedo, Ángel; Lamas, María Jesús; Fernández‐Ferreiro, Anxo
  • imprint: Wiley, 2020
  • Published in: British Journal of Clinical Pharmacology
  • Language: English
  • DOI: 10.1111/bcp.14267
  • ISSN: 0306-5251; 1365-2125
  • Origination:
  • Footnote:
  • Description: <jats:p>Voriconazole is an antifungal metabolised by CYP2C19 enzyme, which can be inhibited by proton‐pump inhibitors (PPIs). A prospective observational study was carried out to determine the influence of PPIs on voriconazole pharmacokinetic. The 78 patients included were divided into 4 groups: omeprazole (<jats:italic>n</jats:italic> = 32), pantoprazole (<jats:italic>n</jats:italic> = 25), esomeprazole (<jats:italic>n</jats:italic> = 3) and no PPI (<jats:italic>n</jats:italic> = 18). Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57–3.69] <jats:italic>vs</jats:italic> 2.11 ± 1.73 μg/mL [95%CI 1.67–2.55], <jats:italic>P</jats:italic> &gt; .05). However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole <jats:italic>vs</jats:italic> those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94–1.94) <jats:italic>vs</jats:italic> 2.67 ± 1.88 μg/mL [95%CI 2.02–3.32], <jats:italic>P</jats:italic> = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole. This study demonstrates the greater CYP inhibition capacity of omeprazole and should be helpful for the choice of PPIs for patients treated with voriconazole.</jats:p>
  • Access State: Open Access